In a phase 3 trial of 615 adults with moderate-to-severe dry eye disease, lifitegrast 5.0% reduced inferior corneal staining at day 84 versus vehicle (P=0.027) and improved eye dryness, discomfort and OSDI scores; no serious ocular adverse events.
RCTn = 615
Lu et al. Lifitegrast ophthalmic solution 5.0% (KH732) for dry eye disease: A randomized, multicenter, double-masked, vehicle-controlled phase 3 trial